Business Context and Reporting Period
This Form 8-K filing by ChromaDex Corp. (not Niagen Bioscience, Inc.) reports corporate governance changes effective December 31, 2013, and January 2, 2014. The filing details the resignation of a director, the appointment of a new director, and adjustments to executive compensation and equity grants.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on personnel and compensation matters.
Material Changes
- Board Resignation: Mr. Curtis Lockshin resigned from the Board of Directors on December 31, 2013. The resignation was not due to any disagreement with the Company.
- Board Appointment: Mr. Steve Allen was appointed to the Board on January 2, 2014. He will serve on the Compensation Committee and chair the Nominating and Corporate Governance Committee.
- Executive Compensation Increases:
- CEO Frank Jaksch Jr.: Base salary raised to $275,000; bonus target raised to 50% of base.
- CFO Thomas Varvaro: Base salary raised to $225,000; bonus target raised to 40% of base.
- Restricted Stock Grants:
- 250,000 shares each to Frank Jaksch Jr., Thomas Varvaro, Michael Brauser, and Barry Honig.
- 50,000 shares to Stephen Block.
- 10,000 shares each to Reid Dabney, Hugh Dunkerley, Mark Germain, and Glenn Halpryn.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. It notes that there are no family relationships between the new director and other officers/directors and no undisclosed arrangements regarding his selection.
Investor Verification Checklist
- Verify the total number of shares outstanding to assess the dilution impact of the 1,000,000 shares of restricted stock granted.
- Review the specific vesting provisions attached to the restricted stock grants, as they are not detailed in this summary.
- Confirm the current composition of the Board of Directors following Mr. Lockshin's departure and Mr. Allen's appointment.
- Check subsequent filings for the Company's financial performance, as this 8-K contains no operational or financial data.